Involvement of ADMA NO pathway in antiatherosclerotic properties of the extract of shi-liang cha in hypercholesterolemic diet-fed rabbits

Abstract

Abstract: AIM: To investigate the effects of the extract of shi-liang cha on atherogenesis in hypercholesterolemic diet-fed rabbits.METHODS: Male rabbits were fed with food containing cholesterol for 8 weeks to induce atherosclerosis.For drug treatment, the animals were orally treated with different doses of the extract of shi-liang cha (25, 50 or 100 mg/kg per day) during the last four-week period of the experiment.At the end of the experiment, blood samples were collected to measure the plasma levels of nitric oxide (NO), asymmetric dimethylarginine (ADMA) and malondialdohyde (MDA), and the aortas were isolated to determine endothelium-dependent vasodilator response and lesion area.RESULTS: The extract of shiliang cha could dose-dependently decrease plasma levels of total cholesterol, low-density lipoprotein and lesion area in atherosclerotic rabbits.Moreover, such treatment could improve endothelium-dependent vasodilator response and erythrocyte deformability, decrease the plasma levels of ADMA and MDA and increase NO content.CONCLUSION: The extract of shi-liang cha lowers blood lipids and inhibits atherogenesis, which may be related to improving endothelial function and erythrocyte deformability via inhibiting lipid peroxidation and modulating ADMA/NO system.

Key words: shi-liang cha, atherosclerosis, endothelium, asymmetric dimethylarginine, lipid peroxidation

CLC Number:

R965.2

DU Wan-hong, LIU Zhong-hua, SHI Ling, ZHOU Zhong-wang, PENG Shi-xi, ZHANG Yong, SHI Zhao-peng, JIANG De-jian. Involvement of ADMA NO pathway in antiatherosclerotic properties of the extract of shi-liang cha in hypercholesterolemic diet-fed rabbits[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(7): 747-752.

References

[1] Vanhoutte PM. Endothelial dy sfunction and atherosclerosis [J]. Eur Heart, 1997, 18(Suppl E): E19-29.
[2] 姜德建, 李元建. 非对称二甲基精氨酸—— 新的心血管疾病危险因子和药物防治靶点[J]. 中国动脉硬化杂志, 2005, 13(3): 379-382.
[3] Päivä H, Lehtimäki T, Laakso J, et al. Dietary composition as a determinant of plasma asymmetric dimethylarginine in subjects with mild hypercholesterolemia[J]. Metabolism, 2004, 53(8): 1072-1075.
[4] Paroni R, Fermo I, Fiorina P, et al. Determination of asymmetric and symmetric dimethylarginines in plasma of hyperhomocysteinemic subjects[J]. Amino Acids, 2005, 28(4): 389-394.
[5] Stangl V, Lorenz M, Stangl K. The role of tea and tea flavonoids in cardiovascular health[J]. Mol Nutr Food Res, 2006, 50(2): 218-228.
[6] Tang WJ, Hu CP, Chen MF, et al. Epigallocatechin gallate preserves endothelial function by reducing the endogenous nitric oxide synthase inhibitor level[J]. Can J Physiol Pharmacol, 2006, 84(2): 163-171.
[7] 杜万红, 刘仲华, 施玲, 等. 花卷茶提取物对高胆固醇血症大鼠血脂和内皮功能的影响[J]. 中南药学,2008, 6(2): 129-133.
[8] Zhou Z, Jiang DJ, Jia SJ, et al. Downregulation of endogenous nitric oxide synthase inhibitors on endothelial SK3 expresion[J]. Vascul Pharmacol, 2007, 47(11): 265-271.
[9] Jiang DJ, Jia SJ, Dai Z, et al. Asymmetric dimethylarginine induces apoptosis via p38MAPK caspase-3-dependent signaling pathway in endothelial cells[J]. JMol Cell Cardiol, 2006, 40(4): 529-539.
[10] Bode-Böger SM, Scalera F, Martens-Lobenhoffer J. Asymmetric dimethylarginine (ADMA) accelerates cell senescence[J]. Vasc Med, 2005, 10(Suppl 1): S65-71.
[11] Böger RH, Bode-Böger SM, Tsao PS, et al. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes[J]. J Am Coll Cardiol, 2000, 36(7): 2287-2295.
[12] Smirnova IV, Kajstura M, Sawamura T, et al. Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation[J]. Am J Physiol Heart Circ Physiol, 2004, 287(2): H782-790.
[13] Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase[J]. Circulation, 1999, 99 (24): 3092-3095.
[14] Tan B, Jiang DJ, Huang H, et al. Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH ADMA pathway[J]. Vascul Pharmacol, 2007, 46(5): 338-345.
[15] 陈美芳, 谢秀梅, 杨天伦, 等. 氯沙坦通过降低ADMA水平诱导血管保护作用[J]. 中南药学, 2007, 5(3): 193-198.
[16] Jiang DJ, Jiang JL, Zhu HQ, et al. Demethylbellidifolin preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level[J]. J Ethnopharmacol, 2004, 93(2/3): 295-306.
[17] 陈稚君, 粱子钧, 张采英. 家兔实验性动脉粥样硬化模型的血液流变学观察[J]. 中华心血管病杂志,1982, 10(4): 297-300.
[18] 王红勇, 何作云, 丁秋华, 等. 实验性高胆固醇血症家兔血液流变特性的改变与AS 形成关系的研究[J]. 中国应用生理学杂志, 2000, 16(3): 231-234.
[19] Tsuda K, Kimura K, Nishio I, et al. Nitric oxide imp roves membrane fluidity of erythrocytes in essential hypertension: an electron paramagnetic resonance investigation[J]. Biochem Biophys Res Commun, 2000, 275(3): 946-954.
[20] BorRucukatay M, Wenby RB, Meiselman HJ, et al. Effects of nitric oxide on red blood cell deformability[J]. Am J Physiol Heart Circ Physiol, 2003, 284(5): H1577-H1584.
[21] Korbut RA, Adamek-Guzik T, Madej J, et al. Endothelial secretogogues and deformability of erythrocytes[J]. Physiol Pharmacol, 2002, 53(4): 655-665.
[22] Xiao HB, Yang ZC, Jia SJ, et al. Effect of asymmetric dimethylarginine on atherogenesis and erythrocyte deformability in apolipoprotein E deficient mice[J]. Life Sci, 2007, 81(1): 1-7.